Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

DVAX Relative to the S&P 500

DVAX Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Dynavax Technologies Corp. (NASD:DVAX) seasonal charts above shows that a Buy Date of May 24 and a Sell Date of October 15 has resulted in a geometric average return of 6.33% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 14 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 23.17% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

To download DVAX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: DVAX